Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AACR 2024 | Resistance to CAR T-cell therapy

Marco Ruella • 9 Apr 2024
AACR 2024
General Lymphoma CAR-T

Marco Ruella, MD, University of Pennsylvania, Philadelphia, PA, outlines an educational session on the resistance to novel therapies, highlighting his presentation on the currently known resistance mechanisms to CAR T-cell therapy. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Marco Ruella

4:34
Access to CAR-T in minority patients with lymphoma in the US: a retrospective analysis
Marco Ruella • 9 Apr 2024
2:44
Do biomarkers exist for predicting response to CAR T-cell therapy?
Marco Ruella • 9 Apr 2024
2:19
First-in-human Phase I trial of AT101, a novel anti-CD19 CAR-T, in R/R NHL
Marco Ruella • 16 Feb 2024
2:40
Bendamustine vs Flu/Cy lymphodepletion prior to CAR-T: reducing rates of toxicity and infection
Marco Ruella • 16 Feb 2024

Related Videos

3:12
Addressing cardiotoxicity following CAR-T therapy and improving clinical practice
Arjun Ghosh • 25 Apr 2024
4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals